Vistin Pharma ASA (OSL:VISTN) ROE % Adjusted to Book Value: 9.31% (As of Mar. 2026)


OSL:VISTN Vistin Pharma ASA OSL:VISTN
80 GF Score
Price kr20.40
GF Value kr25.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA ROE % Adjusted to Book Value?

Vistin Pharma ASA OSL:VISTN 80 ROE % Adjusted to Book Value is 9.31% as of Mar. 2026. GuruFocus rates OSL:VISTN with a GF Score™ of 80/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Vistin Pharma ASA's ROE % for the quarter that ended in Mar. 2026 was 25.32%. Vistin Pharma ASA's PB Ratio for the quarter that ended in Mar. 2026 was 2.72. Vistin Pharma ASA's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 9.31%.


Vistin Pharma ASA ROE % Adjusted to Book Value Related Terms


Vistin Pharma ASA ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA ROE % Adjusted to Book Value Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.91 -0.67 4.78 5.84 8.33

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.28 6.30 7.56 7.12 9.31

OSL:VISTN vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistin Pharma ASA ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's ROE % Adjusted to Book Value falls into.


OSL:VISTN
80GF Score
Vistin Pharma ASA OSL:VISTN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA ROE % Adjusted to Book Value Calculation

Vistin Pharma ASA's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=23.42% / 2.81
=8.33%

Vistin Pharma ASA's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=25.32% / 2.72
=9.31%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 9.31% mean?
Vistin Pharma ASA (OSL:VISTN) has a ROE % Adjusted to Book Value of 9.31% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's ROE % Adjusted to Book Value too high?
Vistin Pharma ASA's current ROE % Adjusted to Book Value is 9.31%. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Vistin Pharma ASA's ROE % Adjusted to Book Value of 9.31% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current ROE % Adjusted to Book Value is 9.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (OSL:VISTN) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.40 — trading 20.3% below its estimated fair value. The current ROE % Adjusted to Book Value is 9.31%. Vistin Pharma ASA's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vistin Pharma ASA (OSL:VISTN), the current ROE % Adjusted to Book Value is 9.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (OSL:VISTN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.40 is trading 20.3% below its estimated GF Value™ of kr25.61. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for OSL:VISTN:

  • ROE % Adjusted to Book Value: 9.31%
  • GF Value™: kr25.61 vs. price of kr20.40 (20.3% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the OSL:VISTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score

Get the complete analysis for OSL:VISTN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.40
Price
kr25.61
GF Value